Evidence map›Paper›PMID 36904292›Full record

Trial reportNutrients2023

Effects of a Synbiotic on Plasma Immune Activity Markers and Short-Chain Fatty Acids in Children and Adults with ADHD-A Randomized Controlled Trial.

Liu L Yang, Miranda Stiernborg, Elin Skott, Jingjing Xu, Yujiao Wu, Rikard Landberg, Samsul Arefin, Karolina Kublickiene, Vincent Millischer, Ida A K Nilsson and 3 more

Registry-linked trialFull text readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07756255 (Feasibility, Safety and Tolerability of Fecal Microbiota Transplantation in an Adolescent Population With Attention Deficit Hyperactivity Disorder), which is not on this map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07756255 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Feasibility, Safety and Tolerability of Fecal Microbiota Transplantation in an Adolescent Population With Attention Deficit Hyperactivity Disorder (ADHD)

TypeinterventionalSponsorUniversity of CalgaryRan2026 to 2029Enrolled64ConditionsADHD, ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined TypeArmsFecal Microbiota Transplant (FMT), Nitazoxanide 500mg BID, Vancomycin 250mg BID, Placebo Vancomycin, Placebo Nitazoxanide
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Add-OnNutrients · 2024
    Trial
  6. Review
  7. Gut Microbiome and ADHD: A Narrative Review of Clinical Evidence and Practice Implications.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Liu L YangDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.ORCID 0000-0002-5963-6295
Miranda StiernborgDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.
Elin SkottDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.
Jingjing XuDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.
Yujiao WuDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 76 Stockholm, Sweden.
Rikard LandbergDepartment of Biology and Biological Engineering, Chalmers University of Technology, 412 96 Gothenburg, Sweden.
Samsul ArefinDivision of Renal Medicine, Department of Clinical Science, Intervention & Technology, Karolinska Institutet, 141 52 Huddinge, Sweden.ORCID 0000-0002-8050-9100
Karolina KublickieneDivision of Renal Medicine, Department of Clinical Science, Intervention & Technology, Karolinska Institutet, 141 52 Huddinge, Sweden.ORCID 0000-0002-4841-6836
Vincent MillischerDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.ORCID 0000-0003-1919-9649
Ida A K NilssonDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.ORCID 0000-0002-7676-4299
Martin SchallingDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.
MaiBritt GiacobiniDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.
Catharina LavebrattDepartment of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.

Funding

Ekhaga Foundation 2016-47Lindhés Advokatbyrå AB LA2019-0013, LA2020-0006Swedish Brain Foundation FO2020-0305, FO2021-0412Swedish Research Council 2014-10171the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet SLL20190589
6 · The paper itself

Abstract

Synbiotic 2000, a pre + probiotic, reduced comorbid autistic traits and emotion dysregulation in attention deficit hyperactivity disorder (ADHD) patients. Immune activity and bacteria-derived short-chain fatty acids (SCFAs) are microbiota-gut-brain axis mediators. The aim was to investigate Synbiotic 2000 effects on plasma levels of immune activity markers and SCFAs in children and adults with ADHD. ADHD patients (n = 182) completed the 9-week intervention with Synbiotic 2000 or placebo and 156 provided blood samples. Healthy adult controls (n = 57) provided baseline samples. At baseline, adults with ADHD had higher pro-inflammatory sICAM-1 and sVCAM-1 and lower SCFA levels than controls. Children with ADHD had higher baseline sICAM-1, sVCAM-1, IL-12/IL-23p40, IL-2Rα, and lower formic, acetic, and propionic acid levels than adults with ADHD. sICAM-1, sVCAM-1, and propionic acid levels were more abnormal in children on medication. Synbiotic 2000, compared to placebo, reduced IL-12/IL-23p40 and sICAM-1 and increased propionic acid levels in children on medication. SCFAs correlated negatively with sICAM-1 and sVCAM-1. Preliminary human aortic smooth-muscle-cell experiments indicated that SCFAs protected against IL-1β-induced ICAM-1 expression. These findings suggest that treatment with Synbiotic 2000 reduces IL12/IL-23p40 and sICAM-1 and increases propionic acid levels in children with ADHD. Propionic acid, together with formic and acetic acid, may contribute to the lowering of the higher-than-normal sICAM-1 levels.

Indexed as

Attention Deficit Disorder with HyperactivitySynbioticsAdultBiomarkersChildFatty Acids, VolatileHumansInterleukin-12PropionatesBiomarkersFatty Acids, VolatileInterleukin-12Propionatespropionic acidacetic acidICAM-1IL-12propionic acidpsychostimulantsVCAM-1

Identifiers

PMID36904292
PMCPMC10004766

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read45
identifiers read1
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.